A detailed history of Ted Buchan & CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Ted Buchan & CO holds 1,600 shares of ABBV stock, worth $374,400. This represents 0.15% of its overall portfolio holdings.

Number of Shares
1,600
Previous 1,587 0.82%
Holding current value
$374,400
Previous $295 Million 25.76%
% of portfolio
0.15%
Previous 0.12%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

BUY
$184.85 - $231.54 $2,403 - $3,010
13 Added 0.82%
1,600 $370 Million
Q2 2024

Aug 21, 2024

BUY
$154.79 - $180.76 $245,651 - $286,866
1,587 New
1,587 $272 Million
Q4 2023

Sep 06, 2024

SELL
$137.6 - $154.97 $6,192 - $6,973
-45 Reduced 2.76%
1,587 $246 Million
Q1 2023

Sep 06, 2024

BUY
$144.61 - $166.54 $11,568 - $13,323
80 Added 5.15%
1,632 $260 Million
Q4 2022

Sep 06, 2024

SELL
$138.31 - $165.87 $4,840 - $5,805
-35 Reduced 2.21%
1,552 $251 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $414B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Ted Buchan & CO Portfolio

Follow Ted Buchan & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ted Buchan & CO, based on Form 13F filings with the SEC.

News

Stay updated on Ted Buchan & CO with notifications on news.